BCAB
Price
$0.21
Change
+$0.02 (+10.53%)
Updated
Feb 6 closing price
Capitalization
13.33M
39 days until earnings call
Intraday BUY SELL Signals
LGVN
Price
$0.51
Change
-$0.00 (-0.00%)
Updated
Feb 6 closing price
Capitalization
11.08M
Intraday BUY SELL Signals
Interact to see
Advertisement

BCAB vs LGVN

Header iconBCAB vs LGVN Comparison
Open Charts BCAB vs LGVNBanner chart's image
BioAtla
Price$0.21
Change+$0.02 (+10.53%)
Volume$3M
Capitalization13.33M
Longeveron
Price$0.51
Change-$0.00 (-0.00%)
Volume$81.21K
Capitalization11.08M
BCAB vs LGVN Comparison Chart in %
BCAB
Daily Signal:
Gain/Loss:
LGVN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
BCAB vs. LGVN commentary
Feb 09, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCAB is a Hold and LGVN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Feb 09, 2026
Stock price -- (BCAB: $0.21 vs. LGVN: $0.51)
Brand notoriety: BCAB and LGVN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCAB: 124% vs. LGVN: 29%
Market capitalization -- BCAB: $13.33M vs. LGVN: $11.08M
BCAB [@Biotechnology] is valued at $13.33M. LGVN’s [@Biotechnology] market capitalization is $11.08M. The market cap for tickers in the [@Biotechnology] industry ranges from $121.26B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCAB’s FA Score shows that 0 FA rating(s) are green whileLGVN’s FA Score has 0 green FA rating(s).

  • BCAB’s FA Score: 0 green, 5 red.
  • LGVN’s FA Score: 0 green, 5 red.
According to our system of comparison, both BCAB and LGVN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCAB’s TA Score shows that 5 TA indicator(s) are bullish while LGVN’s TA Score has 4 bullish TA indicator(s).

  • BCAB’s TA Score: 5 bullish, 4 bearish.
  • LGVN’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, BCAB is a better buy in the short-term than LGVN.

Price Growth

BCAB (@Biotechnology) experienced а -21.71% price change this week, while LGVN (@Biotechnology) price change was -8.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.30%. For the same industry, the average monthly price growth was -2.98%, and the average quarterly price growth was +31.79%.

Reported Earning Dates

BCAB is expected to report earnings on Mar 19, 2026.

Industries' Descriptions

@Biotechnology (-2.30% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCAB($13.3M) has a higher market cap than LGVN($11.1M). LGVN YTD gains are higher at: 1.383 vs. BCAB (-62.903). LGVN has higher annual earnings (EBITDA): -20.98M vs. BCAB (-65.71M). LGVN has more cash in the bank: 9.24M vs. BCAB (8.32M). LGVN has less debt than BCAB: LGVN (983K) vs BCAB (6.18M). LGVN has higher revenues than BCAB: LGVN (1.44M) vs BCAB (0).
BCABLGVNBCAB / LGVN
Capitalization13.3M11.1M120%
EBITDA-65.71M-20.98M313%
Gain YTD-62.9031.383-4,547%
P/E RatioN/A2.95-
Revenue01.44M-
Total Cash8.32M9.24M90%
Total Debt6.18M983K629%
TECHNICAL ANALYSIS
Technical Analysis
BCABLGVN
RSI
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 5 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
88%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
BCAB
Daily Signal:
Gain/Loss:
LGVN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LFWD0.570.03
+5.01%
Lifeward Ltd
SWIM6.600.30
+4.76%
Latham Group
LPLA385.1412.80
+3.44%
LPL Financial Holdings
ANIK10.460.16
+1.55%
Anika Therapeutics
BKU50.930.71
+1.41%
Bankunited

LGVN and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGVN has been loosely correlated with ARCT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if LGVN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGVN
1D Price
Change %
LGVN100%
+0.39%
ARCT - LGVN
50%
Loosely correlated
+7.83%
NTLA - LGVN
48%
Loosely correlated
+10.73%
RXRX - LGVN
47%
Loosely correlated
+11.80%
TPST - LGVN
47%
Loosely correlated
+7.62%
BCAB - LGVN
46%
Loosely correlated
+10.78%
More